How to appeal a UnitedHealthcare copd severe + alpha-1 antitrypsin deficiency denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for copd severe + alpha-1 antitrypsin deficiency

Cited policy: OptumRx Prior Authorization — Dupixent (Dupilumab) for Eosinophilic COPD

Adults with COPD + eosinophilic phenotype (blood eos >=300 cells/uL on >=2 separate determinations off systemic corticosteroids) + on maximal triple inhaled therapy (ICS+LAMA+LABA) for >=3 months + >=2 moderate exacerbations or >=1 hospitalization in past 12 months.

How UnitedHealthcare denies copd severe + alpha-1 antitrypsin deficiency — and how to counter it

Where UnitedHealthcare pushes back: 1) Eos count not documented twice off OCS; 2) Maximal triple not documented; 3) Step therapy through other biologics; 4) Experimental.

Counter-arguments that hold up: FDA approved Sep 27, 2024 — not experimental. BOREAS NEJM 2023 + NOTUS 2024 — 30% exacerbation reduction. GOLD 2024 incorporated dupilumab. Submit ≥2 blood eos determinations off OCS + current ICS/LAMA/LABA prescription history with adherence + exacerbation log with dates and treatment.

What UnitedHealthcare typically denies for copd severe + alpha-1 antitrypsin deficiency

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For copd severe + alpha-1 antitrypsin deficiency, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the copd severe + alpha-1 antitrypsin deficiency treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (eos COPD)
• Ohtuvayre
• Trelegy
• Breztri
• Open triple
• Roflumilast

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.